
|Videos|December 18, 2020
Safety and efficacy of KPI-121 0.25% for DED treatment
Author(s)David Hutton
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% for the treatment of dry eye disease.
Advertisement
Preeya Gupta, MD, discusses the results of a study evaluating the safety and efficacy of KPI-121 0.25% — a nanoparticle ophthalmic suspension of loteprednol etabonate — for the treatment of
Newsletter
Keep your retina practice on the forefront—subscribe for expert analysis and emerging trends in retinal disease management.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Modern Retina
1
Corza Medical announces launch of the SensorTek ROP Kit
2
AGC Biologics to manufacture AAVantgarde’s dual-vector gene therapies, AVB-039 and AAVB-081
3
FLORetina Congress celebrates 10 years with joint World Retinopathy of Prematurity meeting
4
EyePoint receives second consecutive positive recommendation from DSMC
5















































